Brian Stuglik Sells Shares of Puma Biotechnology

Brian Stuglik sold 8,100 shares of Puma Biotechnology in a planned transaction.

Written by EarningsIQ · Published Jun 16, 2026, 2:03 AM EDT · Updated Jun 16, 2026, 2:01 PM EDT

Key Points

Brian Stuglik sold 8,100 shares of Puma Biotechnology (PBYI) on June 12, 2026, in a planned sale valued at $58,320.
Puma Biotechnology, trading at $7.33, has a market cap of $359.9 million and a P/E ratio of 14.73.
Analysts have mixed views, with HC Wainwright reiterating a buy rating and Barclays maintaining a sell rating.

On June 12, 2026, Brian Stuglik sold 8,100 shares of Puma Biotechnology, Inc. (NasdaqGS: PBYI) in a planned transaction. The sale was valued at $58,320, with an average transaction price of $7.20 per share.

Insider Buying and Selling at Puma Biotechnology, Inc.

Several insiders, including Brian Stuglik, made planned sales on June 12, 2026. Stuglik sold 8,100 shares at $7.20 each. Other insiders, such as Dorval Allison and Senderowicz Adrian, also sold shares on the same day under similar planned arrangements.

Other Institutional Activity in Puma Biotechnology

Among institutional investors, Acorn Capital Advisors maintained its position with 4,131,299 shares worth approximately $26.4 million. BlackRock reduced its holdings by 43,636 shares, ending with 3,598,952 shares valued at around $23 million. Acadian Asset Management increased its stake by 16,936 shares, bringing its total to 2,041,759 shares worth about $13 million. Renaissance Technologies cut its position by 181,400 shares, leaving it with 1,942,413 shares valued at $12.4 million. Meanwhile, American Century Companies grew its holdings significantly by 266,209 shares, reaching 1,916,346 shares worth approximately $12.2 million.

Puma Biotechnology Stock Snapshot

Shares of Puma Biotechnology are trading at $7.33. The company has a market cap of approximately $359.9 million and a P/E ratio of 14.73. Its beta is 1.212, indicating moderate volatility. The 52-week range for the stock is between $3.03 and $7.90, with a 50-day moving average of $7.25 and a 200-day moving average of $6.09. Puma Biotechnology maintains a current ratio of 2.38 and a quick ratio of 2.14, with a debt-to-equity ratio of 12.42.

Recent Earnings

Puma Biotechnology reported revenue of $227.2 million, though it saw a slight decline of 2.6% in revenue growth. The company achieved a net margin of 10.7% and a return on equity of 21.6%. The next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

Analysts have varied opinions on Puma Biotechnology. On February 28, 2025, HC Wainwright & Co. reiterated its buy rating with a $7.00 price target. In contrast, on May 3, 2024, Barclays maintained a sell rating with a $2.00 target. The consensus target price is $5.00, based on one analyst's opinion.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company based in Los Angeles, California. The company focuses on developing and commercializing cancer treatments, including NERLYNX, an oral medication for HER2-positive breast cancer. Puma also works on other treatments for various types of cancer and has several licensing agreements, including with Pfizer. Led by CEO Alan H. Auerbach, the company employs 179 people.

Bottom Line

Brian Stuglik's planned sale of Puma Biotechnology shares is part of broader insider activity at the company. Puma Biotechnology continues to be a focal point for institutional investors and analysts, with its stock trading near the upper end of its 52-week range. Investors should note that these insider transactions are planned and do not necessarily indicate any change in the company's outlook.